ELEVAI Labs (NASDAQ: ELAB), a pioneering force in medical aesthetics, has made significant strides of late with the launch of…
Read More »Elevai
The company also reported record Q4 2023 revenue of $698,591, up 403% over the previous quarter. Elevai Labs Inc. (NASDAQ:…
Read More »ELEVAI Labs (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today reported its fiscal 2023 Q3 financial results.…
Read More »ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce its new partnership with…
Read More »ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, announced today the signing of a licensing agreement…
Read More »Shares of Elevai Labs have been approved for listing on the NASDAQ and Will Commence Trading on November 21, 2023,…
Read More »Last Updated: Welcome to Wealthy VC’s Capitalist Countdown The Capitalist Countdown is a weekly series that features the biggest stories from the…
Read More »ELEVAI Labs, a medical aesthetic biotechnology company focused on physician-dispensed skincare and a leader in exosome research and development, is…
Read More »ELEVAI Labs, a medical aesthetic biotechnology company specializing in physician-dispensed skincare, reported today that it secured a stem cell exosome…
Read More »ELEVAI Labs, a science-based, data-driven aesthetic skincare company, will launch its revolutionary core technology platform, PREx™ (Precision Regenerative Exosome Technology™),…
Read More »